Castle Biosciences to Present at the Canaccord Genuity 42nd Annual Growth Conference

Rhea-AI Summary

Castle Biosciences (NASDAQ: CSTL) is set to present a company overview at the Canaccord Genuity 42nd Annual Growth Conference on August 10, 2022, at 1:00 p.m. Eastern time. The presentation will be led by Derek Maetzold, CEO, and Frank Stokes, CFO. Investors can access a live audio webcast on the company's website, with a replay available for two weeks thereafter. Castle specializes in innovative diagnostics for various health conditions, including skin cancers and mental health issues, driving advancements in patient care.

FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Derek Maetzold, president and chief executive officer, and Frank Stokes, chief financial officer, are scheduled to present a company overview at the Canaccord Genuity 42^nd Annual Growth Conference on Wednesday, Aug. 10, 2022, at 1:00 p.m. Eastern time.

A live audio webcast of the Company’s presentation will be available by visiting Castle Biosciences’ website at https://ir.castlebiosciences.com/events-presentations/default.aspx. A replay of the webcast will be available for two weeks following the conclusion of the live broadcast.

About Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.

Castle’s current portfolio consists of tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate-to-severe psoriasis, atopic dermatitis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, Twitter and Instagram.

DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, myPath Melanoma, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq, TissueCypher and IDgenetix are trademarks of Castle Biosciences, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220803005065/en/

Investor Contact:

Camilla Zuckero

czuckero@castlebiosciences.com

Media Contact:

Allison Marshall

amarshall@castlebiosciences.com

Source: Castle Biosciences, Inc.

FAQ

When is Castle Biosciences presenting at the Canaccord Genuity Conference?

Castle Biosciences will present on August 10, 2022, at 1:00 p.m. Eastern time.

Who will represent Castle Biosciences at the conference?

Derek Maetzold, the president and CEO, and Frank Stokes, the CFO, will represent Castle Biosciences.

How can I access the Castle Biosciences conference presentation?

You can access the live audio webcast on Castle Biosciences' website.

What is the stock symbol for Castle Biosciences?

The stock symbol for Castle Biosciences is CSTL.

What type of tests does Castle Biosciences offer?

Castle Biosciences offers tests for skin cancers, uveal melanoma, Barrett’s esophagus, and mental health conditions.